AZACYTIN is a hypomethylating antineoplastic agent used in hematology-oncology. Azacitidine is a cytidine analog that affects DNA and RNA synthesis in abnormal bone marrow cells.
Mechanism of action:
Azacitidine inhibits DNA methyltransferase, leading to DNA hypomethylation and reactivation of genes involved in normal cell differentiation and apoptosis. It also exerts direct cytotoxic effects on rapidly dividing abnormal hematopoietic cells.
Recommended for:
Clinical evidence:
Large randomized trials, including the AZA-001 study, demonstrated improved overall survival in high-risk myelodysplastic syndrome patients treated with azacitidine compared to conventional care regimens. Studies also show reduced transfusion dependence and delayed progression to acute leukemia.
Indicated for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It works by restoring normal regulation of bone marrow cell growth and reducing malignant blast cells.
Administered subcutaneously or intravenously under medical supervision. Treatment is typically given in cycles over several consecutive days followed by rest periods. Duration depends on clinical response and tolerability.
Contraindications
Side Effects
